Skip to main content

Advertisement

SpringerLink
Log in

Two cases of dermatomyositis associated with neuroendocrine tumors

  • Case Report - Complication
  • Published:
International Cancer Conference Journal Aims and scope Submit manuscript

Abstract

Dermatomyositis is an idiopathic inflammatory myopathy with cutaneous manifestations, which is associated with several types of malignancies, yet it has been rarely linked to neuroendocrine tumors (NETs). Here we report two cases of dermatomyositis associated with NETs of differing primary sites. Case 1: A 46-year-old female presented with a facial rash and proximal muscle weakness of both extremities. Investigations revealed elevated creatine kinase (CK) and positive anti-transcriptional intermediary factor 1-γ antibody (TIF1γ). The patient had been diagnosed with dermatomyositis and underwent a total body CT scan, which revealed prominent mediastinal lymphadenopathy, which a subsequent biopsy determined to be neuroendocrine carcinoma of small cell type. Treatment with high-dose corticosteroids was initiated, in addition to chemotherapy-based oncological management. Case 2: A 54-year-old female presented with a facial rash, progressive dyspnea, and general malaise. Laboratory investigations revealed positive anti-melanoma differentiation-associated gene-5 (MDA5) and positive anti-Ro antibody, with a normal level of creatine kinase (CK). A chest CT scan revealed multiple ground-glass opacities. Despite treatment with high-dose intravenous methylprednisolone, IVIG and an infusion of the anti-IL-6 sarilumab [Kevzara], the patient rapidly deteriorated and was intubated. Within days, the patient developed bowel ischemia and underwent a laparotomy which was then complicated by an invasive infection. This resulted in patient’s death. Pathology results from colonic tissue demonstrated an appendiceal neuroendocrine tumor. These cases demonstrate the heterogeneity and complexity of dermatomyositis in association with neuroendocrine tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Selva-O’Callaghan A, Pinal-Fernandez I, Trallero-Araguás E et al (2018) Classification and management of adult inflammatory myopathies. Lancet Neurol 17:816–828

    Article  PubMed  Google Scholar 

  2. Cobos GA, Femia A, Vleugels RA (2020) Dermatomyositis: an update on diagnosis and treatment. Am J Clin Dermatol 21:339–353

    Article  PubMed  Google Scholar 

  3. Sasaki H, Kohsaka H (2018) Current diagnosis and treatment of polymyositis and dermatomyositis. Mod Rheumatol 28:913–921

    Article  PubMed  CAS  Google Scholar 

  4. Yang Z, Lin F, Qin B et al (2015) Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol 42:282–291. https://doi.org/10.3899/JRHEUM.140566

    Article  PubMed  Google Scholar 

  5. Wang J, Guo G, Chen G et al (2013) Meta-analysis of the association of dermatomyositis and polymyositis with cancer. Br J Dermatol 169:838–847. https://doi.org/10.1111/BJD.12564

    Article  PubMed  CAS  Google Scholar 

  6. Buchbinder R, Forbes A, Hall S et al (2001) Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med. https://doi.org/10.7326/0003-4819-134-12-200106190-00008

    Article  PubMed  Google Scholar 

  7. Hsu JL, Liao MF, Chu CC et al (2021) (2021) Reappraisal of the incidence, various types and risk factors of malignancies in patients with dermatomyositis and polymyositis in Taiwan. Sci Reports 111(11):1–11. https://doi.org/10.1038/s41598-021-83729-5

    Article  CAS  Google Scholar 

  8. Shalata W, Zolnoorian J, Meirovitz A, et al (2022) Dermatomyositis Associated with Lung Cancer: A Brief Review of the Current Literature and Retrospective Single Institution Experience. Life (Basel, Switzerland) https://doi.org/10.3390/LIFE13010040

  9. Qiang JK, Kim WB, Baibergenova A, Alhusayen R (2017) Risk of malignancy in dermatomyositis and polymyositis: a systematic review and meta-analysis. J Cutan Med Surg 21:131–136

    Article  PubMed  Google Scholar 

  10. Leatham H, Schadt C, Chisolm S et al (2018) Evidence supports blind screening for internal malignancy in dermatomyositis: Data from 2 large US dermatology cohorts. Med (United States). https://doi.org/10.1097/MD.0000000000009639

    Article  Google Scholar 

  11. Oronsky B, Ma PC, Morgensztern D, Carter CA (2017) Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia (United States) 19:991–1002

    Article  CAS  Google Scholar 

  12. La Rosa S, Uccella S (2021) Classification of neuroendocrine neoplasms: lights and shadows. Rev Endocr Metab Disord 22:527–538

    Article  PubMed  Google Scholar 

  13. Lee WY, Kastelik J, Campbell A et al (2012) A case report of dermatomyositis associated with small cell lung cancer. Tumori 98:e158

    Article  Google Scholar 

  14. Yu K-L, Ho C-C (2016) Dermatomyositis as the initial presentation of small cell lung cancer: a case report. Thorac Med 31:215–221

    Google Scholar 

  15. Takashima R, Takamatsu K, Shinkawa Y et al (2017) Dermatomyositis associated with lung neuroendocrine carcinoma. Intern Med 56:719–724. https://doi.org/10.2169/internalmedicine.56.7768

    Article  PubMed  PubMed Central  Google Scholar 

  16. Arnon J, Elia A, Nevo Y, et al (2021) SCLC, Paraneoplastic dermatomyositis, positive transcription intermediary factor 1-γ, and point mutation in the transcription intermediary factor 1-γ coding gene: a case report. JTO Clin Res Reports 2

  17. Kato T, Ito S, Tsuzuki T, et al (2019) Small cell lung cancer and interstitial pneumonia associated with anti-transcriptional intermediary factor-1γ-positive dermatomyositis. Respirol Case Reports 7

  18. Sheng-Hua Su, Yeh P-F, Te A, Kwang W-K (2014) Small cell lung cancer with paraneoplastic dermatomyositis: a case report. Thorac Med 29:377–383

    Google Scholar 

  19. Zhang T, Wu Q, Qin S et al (2019) Lung cancer with dermatomyositis as the initial diagnosis: a case report. Mol Clin Oncol 11:59–62. https://doi.org/10.3892/MCO.2019.1851/DOWNLOAD

    Article  PubMed  PubMed Central  Google Scholar 

  20. Ly NTM, Ma N, Ueda-Hayakawa I et al (2021) Clinical and laboratory parameters predicting cancer in dermatomyositis patients with anti-TIF1γ antibodies. J Dermatol Sci 104:177–184. https://doi.org/10.1016/J.JDERMSCI.2021.10.003

    Article  PubMed  CAS  Google Scholar 

  21. Mcvera RM, Crawford LJ (2020) TIF1 proteins in genome stability and cancer. Cancers 12:2094. https://doi.org/10.3390/CANCERS12082094

    Article  Google Scholar 

  22. De Vooght J, Vulsteke JB, De Haes P et al (2020) Anti-TIF1-γ autoantibodies: warning lights of a tumour autoantigen. Rheumatology 59:469–477. https://doi.org/10.1093/RHEUMATOLOGY/KEZ572

    Article  PubMed  Google Scholar 

  23. Fiorentino DF, Chung LS, Christopher-Stine L et al (2013) Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum 65:2954–2962. https://doi.org/10.1002/ART.38093

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  24. Best M, Molinari N, Chasset F et al (2019) Use of Anti-transcriptional intermediary factor-1 gamma autoantibody in identifying adult dermatomyositis patients with cancer: a systematic review and meta-analysis. Acta Derm Venereol 99:256–262. https://doi.org/10.2340/00015555-3091

    Article  PubMed  CAS  Google Scholar 

  25. McHugh NJ, Tansley SL (2018) Autoantibodies in myositis. Nat Rev Rheumatol 14:290–302. https://doi.org/10.1038/nrrheum.2018.56

    Article  PubMed  CAS  Google Scholar 

  26. Nombel A, Fabien N, Coutant F (2021) Dermatomyositis with anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies. Front Immunol. https://doi.org/10.3389/FIMMU.2021.773352

    Article  PubMed  PubMed Central  Google Scholar 

  27. Gono T, Sato S, Kawaguchi Y et al (2012) Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology 51:1563–1570. https://doi.org/10.1093/RHEUMATOLOGY/KES102

    Article  PubMed  CAS  Google Scholar 

  28. Ceribelli A, Fredi M, Taraborelli M et al (2014) Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis. Clin Exp Rheumatol 32:891–897

    PubMed  Google Scholar 

  29. Labrador-Horrillo M, Martinez MA ngele, Selva-O’Callaghan A, et al (2014) Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis. J Immunol Res https://doi.org/10.1155/2014/290797

  30. Cao H, Pan M, Kang Y et al (2012) Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody. Arthritis Care Res (Hoboken) 64:1602–1610. https://doi.org/10.1002/ACR.21728

    Article  PubMed  Google Scholar 

  31. Griniatsos J (2010) Appendiceal neuroendocrine tumors: Recent insights and clinical implications. World J Gastrointest Oncol 2:192

    Article  PubMed  PubMed Central  Google Scholar 

  32. Rodríguez P L, Yurgaky S J, Otero RW, Faizal M (2017) Síndromes paraneoplásicos en tumores gastrointestinales. Revisión de tema. Rev Colomb Gastroenterol 32:230–244. https://doi.org/10.22516/25007440.155

  33. dos Anjos CS, Lisita Rosa VD, Godoy ACC, et al (2015) Paraneoplastic dermatomyositis associated with neuroendocrine tumor of an unknown primary site: a case report. Clin Case Reports Rev 1

  34. Hozumi H, Fujisawa T, Nakashima R et al (2016) Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease. Respir Med 121:91–99. https://doi.org/10.1016/j.rmed.2016.10.019

    Article  PubMed  Google Scholar 

  35. Xing X, Li A, Li C (2020) Anti-Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis. Respir Med 172:106134. https://doi.org/10.1016/j.rmed.2020.106134

    Article  PubMed  Google Scholar 

  36. Betteridge Z, McHugh N (2016) Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med 280:8–23. https://doi.org/10.1111/JOIM.12451

    Article  PubMed  CAS  Google Scholar 

  37. Koga T, Fujikawa K, Horai Y et al (2012) The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology 51:1278–1284. https://doi.org/10.1093/RHEUMATOLOGY/KER518

    Article  PubMed  CAS  Google Scholar 

  38. Nakashima R, Imura Y, Kobayashi S et al (2010) The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford) 49:433–440. https://doi.org/10.1093/RHEUMATOLOGY/KEP375

    Article  PubMed  CAS  Google Scholar 

  39. Hamaguchi Y, Kuwana M, Hoshino K et al (2011) Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol 147:391–398. https://doi.org/10.1001/ARCHDERMATOL.2011.52

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine B, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel

    Uria Shani, Noy Lavine, Esther Houri-Levi, Abdalla Watad & Howard Amital

Authors
  1. Uria Shani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Noy Lavine
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Esther Houri-Levi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Abdalla Watad
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Howard Amital
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Uria Shani.

Ethics declarations

Conflict of interest

None.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shani, U., Lavine, N., Houri-Levi, E. et al. Two cases of dermatomyositis associated with neuroendocrine tumors. Int Canc Conf J 13, 17–21 (2024). https://doi.org/10.1007/s13691-023-00629-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13691-023-00629-3

Keywords

Search

Navigation